For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-5353 TELEFLEX INCORPORATED (Exact name of registrant as specified in its charter) Delaware 23-1147939 (State or other jurisdicti ...

Financial Data and Key Metrics Changes - For Q1 2024, the company reported revenues of $737.8 million, a 3.8% increase year-over-year on both GAAP and constant currency basis [83] - Adjusted earnings per share (EPS) for the first quarter was $3.21, reflecting a 3.9% increase compared to the prior year [7][83] - Net interest expense increased to $21 million from $17.5 million in the prior year, primarily due to higher interest rates and increased debt from the Palette acquisition [7] - Adjusted gross margin was 61.1%, a 170 basis point increase year-over-year, driven by the termination of the MSA and the acquisition of Palette [64] - The adjusted tax rate for Q1 2024 was 13.2%, up from 11.8% in the prior year, mainly due to European tax reforms [7] Business Line Data and Key Metrics Changes - Interventional Urology revenue was $79.7 million, a 6.1% increase year-over-year, driven by Barrigel revenue from the Palette acquisition [5] - Interventional revenue increased by 15.4% year-over-year to $134.7 million, led by balloon pumps and complex catheters [61] - Surgical business revenue was $105.5 million, a 7.1% increase year-over-year, with strong performance in chest drainage instrumentation [61] - OEM revenue grew 13.6% year-over-year to $87.7 million, with strong demand for microcatheters [85] Market Data and Key Metrics Changes - Americas revenues decreased by 1.5% year-over-year to $406.3 million, impacted by the loss of MSA revenues [4] - EMEA revenues increased by 9.7% year-over-year to $159.6 million, with double-digit growth in interventional and interventional urology [4] - Asia revenues were $84.2 million, an 11.2% increase year-over-year, with strong growth in China, India, and Southeast Asia [84] Company Strategy and Development Direction - The company aims to drive durable growth through organic opportunities and innovation, while also focusing on disciplined capital allocation [68] - The integration of Palette Life Sciences is progressing well, expected to contribute significantly to growth in the coming years [68] - The company is focused on tuck-in acquisitions and scale transactions, with a strong emphasis on maintaining a disciplined approach to M&A [25][110] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2024 revenue growth guidance of 3.75% to 4.75%, despite the loss of MSA revenues [8] - The company anticipates a positive trend in gross margins and operating margins, with expectations for continued improvement in the second half of 2024 [48][66] - Management noted that the operating environment remains strong, with utilization of products returning to pre-pandemic levels [83] Other Important Information - The company expects a foreign exchange headwind of approximately $12 million for 2024, impacting revenue growth [89] - Cash flow from operations for Q1 was $112.8 million, an increase from $84.3 million in the prior year, attributed to favorable operating results [88] - The company is actively training sales representatives for the Palette product line, with full integration expected by the end of 2024 [62] Q&A Session Summary Question: What are the drivers of growth for Palette? - Management indicated that growth for Palette is primarily driven by market expansion and adoption within the existing customer base, with additional sales representatives expected to enhance market presence [39] Question: Why was the full-year guidance not raised despite a strong Q1? - Management explained that while Q1 performance was strong, the guidance was conservative due to the need to monitor ongoing trends and the impact of foreign exchange [20][38] Question: What is the outlook for UroLift? - Management confirmed expectations for UroLift to achieve 7.5% growth in 2024, despite challenges in the office side of service and sales force training [115] Question: How does the company view the competitive landscape in the OEM business? - Management noted that while there is competitive noise, the underlying demand remains strong, and they anticipate double-digit growth for OEM throughout the year [69] Question: What are the expectations for gross margin expansion in 2025? - Management expressed optimism about gross margin expansion due to continuous improvement programs and the ramp-up of Palette, which is expected to become accretive to operating margins [145]

Exhibit 99.1 FOR IMMEDIATE RELEASE May 2, 2024 Teleflex Reports First Quarter Financial Results and Full Year 2024 Outlook Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the first quarter ended March 31, 2024. First quarter financial summary 1 • Revenues of $737.8 million, up 3.8% compared to the prior year period; up 3.8% on a constant currency basis • GAAP diluted EPS from continuing operations of $0.33, compared to $1.63 in the prior year period • Adj ...

Financial Performance - Net revenues for 2023 were $2,974.5 million, up from $2,791.0 million in 2022[340] - Gross profit increased to $1,646.9 million in 2023 from $1,531.1 million in 2022[340] - Net income for 2023 was $356.3 million, compared to $363.1 million in 2022 and $485.4 million in 2021[343] - Comprehensive income for 2023 was $445.4 million, up from $306.6 million in 2022 and $435.7 million in 2021[343] - Net cash provided by operating activities from continuing operations increased to $511.7 million in 2023, up from $342.8 million in 2022[242] - Free cash flow rose to $420.2 million in 2023, compared to $263.6 million in 2022[242] - Net cash provided by financing activities from continuing operations was $38.5 million in 2023, primarily due to $101.3 million in net proceeds from borrowings for the acquisition of Palette[239] - Net revenues for the year ended December 31, 2023, were $2,974.5 million, compared to $2,791.0 million in 2022 and $2,809.6 million in 2021[386] International Operations - 72% of the company's full-time employees were employed outside the U.S., and 58% of net property, plant, and equipment was located outside the U.S. as of December 31, 2023[127] - 37% of net revenues for 2023 were derived from operations outside the U.S.[127] - Asia net revenues for 2023 increased by $40.6 million (13.2%), driven by a $25.5 million increase in sales volume of existing products and an $18.8 million increase in sales of new products[220] - Asia operating profit for 2023 increased by $7.3 million (8.8%), primarily due to higher sales[221] - Cash and cash equivalents as of December 31, 2023, totaled $222.8 million, with $196.7 million held at non-U.S. subsidiaries[227] Acquisitions and Contingent Liabilities - Contingent consideration liabilities as of December 31, 2023, amounted to $39.5 million, primarily related to acquisitions of Standard Bariatrics Inc. and Palette[121] - The company completed the acquisition of Palette on October 10, 2023, with a fair value of consideration transferred of $621.9 million[335] - Identifiable intangible assets acquired in the Palette acquisition included $264.0 million in intellectual property and $40.5 million in trade names intangible assets[335] - The company completed the acquisition of Palette Life Sciences AB for $621.9 million, including $594.9 million in net cash payments and $27.0 million in contingent consideration[388] - The Palette acquisition added $333.5 million in intangible assets and $357.0 million in goodwill[390] - The fair value of contingent consideration liabilities was $39.5 million as of December 31, 2023[461] - Contingent consideration liabilities decreased from $44.0 million at the beginning of 2023 to $39.5 million by the end of 2023, primarily due to revaluations and adjustments[472] - The maximum potential payment under contingent consideration arrangements related to acquisitions is $177.0 million[468] - Revenue volatility for contingent consideration liabilities ranges from 15.1% to 20.3%, with a weighted average of 18.8%[470] Segment Performance - OEM net revenues for 2023 increased by $53.4 million (19.6%), driven by a $28.3 million increase in sales volume of existing products and price increases[222] - OEM operating profit for 2023 increased by $20.8 million (31.9%), primarily due to price increases and higher sales[223] - The OEM segment revenue increased to $326.0 million in 2023 from $272.6 million in 2022[386] - The Vascular Access product category generated $708.0 million in revenue for 2023, up from $683.6 million in 2022[386] Balance Sheet and Cash Flow - Total assets increased to $7.53 billion in 2023 from $6.93 billion in 2022, driven by growth in goodwill and intangible assets[346] - Goodwill increased to $2.91 billion in 2023 from $2.54 billion in 2022, reflecting acquisitions and business combinations[346] - Retained earnings grew to $4.11 billion in 2023 from $3.82 billion in 2022, supported by net income generation[349] - Cash and cash equivalents decreased to $222.8 million in 2023 from $292.0 million in 2022, reflecting cash usage for operations and investments[346] - Total liabilities increased to $3.09 billion in 2023 from $2.91 billion in 2022, primarily due to higher long-term borrowings[346] - The company had $262.0 million in borrowings outstanding and $0.9 million in outstanding standby letters of credit under its $1.0 billion revolving credit facility as of December 31, 2023[245] - The company borrowed the maximum amount available of $75 million under its accounts receivable securitization facility as of December 31, 2023[248] Risk Management and Derivatives - The company entered into a zero-cost foreign exchange collar contract in December 2023 to manage foreign exchange risk related to $500 million notional cross-currency swaps[229] - A 1.0% change in variable interest rates would impact annual interest expense by $8.2 million based on outstanding debt as of December 31, 2023[279] - Derivative assets valued at $63.6 million and derivative liabilities at $1.5 million, both classified under Level 2 of the fair value hierarchy[463] Shareholder Equity and Shares - Basic weighted average shares outstanding for 2023 were 46.98 million, with a dilutive effect of 0.32 million shares from share-based awards, resulting in diluted shares of 47.30 million[474] - The company has 200 million authorized common shares and 500,000 preference shares, with no preference shares outstanding in the last three years[473] Reserves and Allowances - The liability for returns and allowances was $22.2 million as of December 31, 2023, up from $17.9 million in 2022[379] - The reserve for customer incentive programs, including rebates, was $26.7 million as of December 31, 2023, down from $29.0 million in 2022[379] Investments and Fair Value - Investments in marketable securities valued at $10.1 million as of December 31, 2022, classified under Level 1 of the fair value hierarchy[463] - Contingent consideration liabilities valued at $44.0 million as of December 31, 2022, classified under Level 3 of the fair value hierarchy[463] Transaction Expenses - The company incurred $10.6 million in transaction expenses related to the Palette acquisition[391] Goodwill and Impairment - The company did not record any goodwill impairment charges for the year ended December 31, 2023[360] Revenue Sources - The company's revenue from hospitals and healthcare providers represented 87% of consolidated net revenues for the year ended December 31, 2023[377] Obligor Group Performance - Obligor Group net revenue for 2023 was $2,128.2 million, with gross profit of $764.9 million and net income of $259.5 million[233]

Teleflex Incorporated (NYSE:TFX) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET Company Participants Lawrence Keusch - Vice President of Investor Relations and Strategy Development Liam Kelly - Chairman, President and CEO Thomas Powell - Executive Vice President and CFO Conference Call Participants Patrick Wood - Morgan Stanley Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Michael Sarcone - Jefferies Larry Biegelsen - Wells Fargo Matthew O'Brien - Piper Sandler Mike ...

Exhibit 99.1 FOR IMMEDIATE RELEASE February 22, 2024 Teleflex Reports Fourth Quarter and Full Year 2023 Financial Results Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the fourth quarter ended December 31, 2023. Fourth quarter financial summary Full year 2023 financial summary 2024 guidance summary "We demonstrated solid execution during the fourth quarter against a stable to improving macro-environment," said Liam Kelly, Teleflex's Chairman, President ...

Teleflex Incorporated (NYSE:TFX) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Lawrence Keusch - Vice President of Investor Relations and Strategy Development Liam Kelly - Chairman, President and Chief Executive Officer Thomas Powell - Executive Vice President and Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Jayson Bedford - Raymond James Shagun Singh - RBC Mike Sarcone - Jefferies Vik Chopra - Wells Fargo George Sellers - Stephens In ...

| --- | --- | --- | |---------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Teleflex Incorporated Third Quarter 2023 Earnings Conference Call | | | The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) The confirmation code is 87648. Liam Kelly Chairman, President and CEO Tfeleflex® Note on Forward-Looking Statements Conference Call Logistics The call can be accessed by dialing 1 800 770 20 ...

| --- | --- | --- | |----------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Teleflex Incorporated Second Quarter 2023 Earnings Conference Call | | | The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) 2 Conference Call Logistics The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 647 362 9199 (all other locations). Today's Speakers Thomas Powell Executive VP and CFO Tfeleflex® ...